Designing potent inhibitors against the multidrug resistance P-glycoprotein
- 1 June 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 40 (19) , 9403-9415
Abstract
The multidrug transporter P-glycoprotein is an ATP binding cassette (ABC) exporter responsible for resistance to tumor cells during chemotherapy. This study was designed with computational approaches aimed at identifying the best potent inhibitors of P-glycoprotein. Although many compounds have been suggested to inhibit P-glycoprotein, however, their information on bioavailability, selectivity, ADMET properties, and molecular interactions has not been revealed. Molecular docking, ADMET analysis, molecular dynamics, Principal component analysis (PCA), and binding free energy calculations were performed. Two compounds D1 and D2 showed the best docking score against P-glycoprotein and both compounds have 4-thiazolidinone derivatives containing indolin-3 one moiety are novel anti-tumor compounds. ADMET calculation analysis predicted D1 and D2 to have acceptable pharmacokinetic properties. The MD simulation discloses that D1-P-glycoprotein and D2-P-glycoprotein complexes are in stable conformation as apo-form. Hydrophobic amino acid such as phenylalanine plays significant on the interactions of inhibitors. Principal component analysis shows that both complexes are relatively similar variables as apo-form except planarity and Columbo energy profile. In addition, Quantitative Structural Activity Relationship (QSAR) of the ligand candidates were subjected to the principal component analysis (PCA) for pattern recognition. Partial-least-square (PLS) regression analysis was further utilized to model drug candidates’ QSAR for subsequent prediction of the binding energy of validated drug candidates. PCA revealed groupings of the drug candidates based on the similarity or differences in drug candidates QSAR. Moreover, the developed PLS regression accurately predicted the values of the binding energy of drug candidates, with low residual error of prediction. Communicated by Ramaswamy H. SarmaKeywords
This publication has 79 references indexed in Scilit:
- QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase‐IJournal of Chemometrics, 2013
- admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET PropertiesJournal of Chemical Information and Modeling, 2012
- The P-glycoprotein multidrug transporterEssays in Biochemistry, 2011
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- Evidence for a Sav1866‐like architecture for the human multidrug transporter P‐glycoproteinThe FASEB Journal, 2007
- A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer PatientsClinical Cancer Research, 2007
- BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinitiesNucleic Acids Research, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- The Protein Data BankNucleic Acids Research, 2000
- Clinical trials of p-glycoprotein reversal in solid tumoursEuropean Journal of Cancer, 1996